Overview of Hepatitis C and Skin

Connie M. Chung; Julia R. Nunley


Dermatology Nursing. 2006;18(5):425-430. 

In This Article

Treatment-Associated Disorders

Pegylated interferon-alpha with ribavirin is the standard of care for treating chronic HCV infection. Interferon causes cutaneous reactions in about 10% of patients (Stafford-Fox & Guindon, 2000). Most of these are nonspecific eczematous and lichenoid reactions (Sookoian et al., 1999); however, interferon also has been associated with the development of psoriasis, vitiligo, and sarcoidosis (Hurst & Mauro, 2005; Simsek, Savas, Akkiz, & Telatar, 1996). Although rare, ribavirin can trigger a photosensitivity reaction to ultraviolet B light (Dereure, Raison-Peyron, Larrey, Blanc, & Guilhou, 2002). Combination therapy increases the incidence of cutaneous reactions to 30%. Again, most are nonspecific reactions and are rarely cause for cessation of therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.